Fredun Pharmaceuticals surges after Q1 PAT rises 94% YoY to Rs 13 crore
Mumbai, Aug. 5 -- Revenue from operations rose by 90.7% year-on-year (YoY) to Rs 227.75 crore during the period under review.
Total expenses rose by 86.6% to Rs 206.79 crore in Q1 FY27 from Rs 110.81 crore in Q1 FY26. This was primarily due to higher raw material costs (up 97.6% YoY), higher depreciation charges (up 151.6% YoY) and higher other expenses (up 52.5% YoY).
Profit before tax in Q1 FY27 stood at Rs 20.55 crore, up 127.3% from Rs 9.04 crore in Q1 FY26.
Fredun Pharmaceuticals manufactures pharmaceutical formulations such as tablets, syrups, capsules, and ointments. The company's product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral, anti-hypertensive etc.
Published by HT Digital Content ...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.